368 related articles for article (PubMed ID: 11830510)
1. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Ristimäki A; Sivula A; Lundin J; Lundin M; Salminen T; Haglund C; Joensuu H; Isola J
Cancer Res; 2002 Feb; 62(3):632-5. PubMed ID: 11830510
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E; Tang XM; Gwyn K; Sahin A; Wathen K; Sinicrope FA
Cancer Res; 2002 Mar; 62(6):1676-81. PubMed ID: 11912139
[TBL] [Abstract][Full Text] [Related]
3. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer.
Sivula A; Talvensaari-Mattila A; Lundin J; Joensuu H; Haglund C; Ristimäki A; Turpeenniemi-Hujanen T
Breast Cancer Res Treat; 2005 Feb; 89(3):215-20. PubMed ID: 15754118
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.
Denkert C; Winzer KJ; Müller BM; Weichert W; Pest S; Köbel M; Kristiansen G; Reles A; Siegert A; Guski H; Hauptmann S
Cancer; 2003 Jun; 97(12):2978-87. PubMed ID: 12784332
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
Ranger GS; Jewell A; Thomas V; Mokbel K
J Surg Oncol; 2004 Nov; 88(2):100-3. PubMed ID: 15499599
[TBL] [Abstract][Full Text] [Related]
6. Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma.
Lim SC
Oncol Rep; 2003; 10(5):1241-9. PubMed ID: 12883688
[TBL] [Abstract][Full Text] [Related]
7. Expression of cyclooxygenase-2 in malignant and benign breast tumors.
Watanabe O; Shimizu T; Imamura H; Kinoshita J; Utada Y; Okabe T; Kimura K; Hirano A; Yoshimatsu K; Aiba M; Ogawa K
Anticancer Res; 2003; 23(4):3215-21. PubMed ID: 12926055
[TBL] [Abstract][Full Text] [Related]
8. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer.
Ranger GS; Thomas V; Jewell A; Mokbel K
Anticancer Res; 2004; 24(4):2349-51. PubMed ID: 15330183
[TBL] [Abstract][Full Text] [Related]
9. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
Arun B; Kilic G; Yen C; Foster B; Yardley DA; Gaynor R; Ashfaq R
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1681-5. PubMed ID: 16030101
[TBL] [Abstract][Full Text] [Related]
10. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 expression in postmastectomy chest wall relapse.
Kim JH; Bossuyt V; Ponn T; Lannin D; Haffty BG
Clin Cancer Res; 2005 Jul; 11(14):5199-205. PubMed ID: 16033837
[TBL] [Abstract][Full Text] [Related]
12. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer.
Linder N; Lundin J; Isola J; Lundin M; Raivio KO; Joensuu H
Clin Cancer Res; 2005 Jun; 11(12):4372-81. PubMed ID: 15958620
[TBL] [Abstract][Full Text] [Related]
13. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
Shim V; Gauthier ML; Sudilovsky D; Mantei K; Chew KL; Moore DH; Cha I; Tlsty TD; Esserman LJ
Cancer Res; 2003 May; 63(10):2347-50. PubMed ID: 12750248
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Shono T; Tofilon PJ; Bruner JM; Owolabi O; Lang FF
Cancer Res; 2001 Jun; 61(11):4375-81. PubMed ID: 11389063
[TBL] [Abstract][Full Text] [Related]
16. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.
Heinonen M; Bono P; Narko K; Chang SH; Lundin J; Joensuu H; Furneaux H; Hla T; Haglund C; Ristimäki A
Cancer Res; 2005 Mar; 65(6):2157-61. PubMed ID: 15781626
[TBL] [Abstract][Full Text] [Related]
18. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma.
Denkert C; Weichert W; Winzer KJ; Müller BM; Noske A; Niesporek S; Kristiansen G; Guski H; Dietel M; Hauptmann S
Clin Cancer Res; 2004 Aug; 10(16):5580-6. PubMed ID: 15328200
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma.
Nakopoulou L; Mylona E; Papadaki I; Kapranou A; Giannopoulou I; Markaki S; Keramopoulos A
Pathobiology; 2005; 72(5):241-9. PubMed ID: 16374068
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer.
Huang J; Tan PH; Thiyagarajan J; Bay BH
Mod Pathol; 2003 Jun; 16(6):558-65. PubMed ID: 12808061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
